Actavis plc has entered into an agreement with Pfizer, Inc. to settle all outstanding patent litigation related to Actavis’ generic version of Celebrex^® (celecoxib) 50-mg, 100-mg, 200-mg and 400-mg capsules. Celebrex^® is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults.

Under the terms of the agreement, Pfizer will grant Actavis a license to market its generic Celebrex^® beginning in December 2014, or earlier under certain circumstances.  Other details of the settlement were not disclosed.

Launch of Actavis’ product is contingent upon Actavis receiving final approval from FDA on its abbreviated new drug application (ANDA) for generic Celebrex^®. 

For the 12 months ending December 31, 2013, Celebrex^® had total US sales of approximately $2.2 billion, according to IMS Health data, and as reported by Actavis

Earlier this month, Pfizer had also reached a settlement for generic Celebrex with Teva Pharmaceutical Industries.

Source: Actavis